MDxHealth
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 jul 2008 - 12:49
Statutaire naam
MDxHealth
Titel
Methylation Assay for Colorectal Cancer Screening Launched by LabCorp
Bericht
OncoMethylome’s methylation detection technology is used in the new ColoSureTM colorectal cancer screening assay
Liege (Belgium) – July 15, 2008, 08:00 CET – OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that Laboratory Corporation of America® Holdings (LabCorp®) launched ColoSureTM, a stool-based testing service for colorectal cancer screening which is included in the American Cancer Society’s colorectal cancer screening guidelines. The testing service is carried out with reagents for detecting methylation of the Vimentin DNA marker with Methylation-Specific PCR (MSP) technology. As announced in a press release dated June 23, 2008, OncoMethylome earns revenue for supplying LabCorp with these reagents and qualifies for milestones tied to commercial uptake of the reagents by LabCorp.
“This is the second methylation assay launched by LabCorp in 2008. We are pleased with LabCorp’s commitment to make OncoMethylome’s methylation technology available to patients. We hope this test, for colorectal cancer screening, will help to detect colorectal cancer that would otherwise have been undetected and untreated” commented Herman Spolders, CEO of OncoMethylome.
Gerelateerde downloads
Datum laatste update: 01 september 2024